Evidence mapPaperPMID 41566484Full record

ArticleFluids and barriers of the CNS2026

Brain capillary endothelial-like cells show altered barrier functionality and reduced transport of amyloid β in late-onset Alzheimer disease.

Carla Hartmann, Undine Haferkamp, Antje Appelt-Menzel, Janica Barenberg, Andreas Brachner, Toni Ehrhard, Julia Feldhaus, Anna Gerhartl, Thomas Hollemann, Linda Anna Michelle Kulka and 14 more

Abstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Carla Hartmann *Institute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Undine Haferkamp *Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research Screening Port, 22525, Hamburg, Germany.
Antje Appelt-MenzelFraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies (TLC-RT), 97070, Würzburg, Germany.
Janica BarenbergFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research Screening Port, 22525, Hamburg, Germany.
Andreas BrachnerCenter Health and Bioresources, Competence Unit Molecular Diagnostics, AIT Austrian Institute of Technology GmbH, Vienna, 1210, Austria.
Toni EhrhardInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Julia FeldhausInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Anna GerhartlCenter Health and Bioresources, Competence Unit Molecular Diagnostics, AIT Austrian Institute of Technology GmbH, Vienna, 1210, Austria.
Thomas HollemannInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Linda Anna Michelle KulkaInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Selin LeckzikInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Jennifer LeuFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research Screening Port, 22525, Hamburg, Germany.
Marcel Seungsu WooTranslational Neurodegeneration Laboratory, Department of Neurology, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Manuel Alexander FrieseInstitute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Alzheimer's Disease Neuroimaging Initiative
Marco MetzgerFraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies (TLC-RT), 97070, Würzburg, Germany.
Winfried NeuhausCenter Health and Bioresources, Competence Unit Molecular Diagnostics, AIT Austrian Institute of Technology GmbH, Vienna, 1210, Austria.
Sabrina OerterFraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies (TLC-RT), 97070, Würzburg, Germany.
Heidi OlzschaInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany.
Andreas PichInstitute of Toxicology, Hannover Medical School, 30625, Hannover, Germany.
Dagmar RiemannDepartment Medical Immunology, Martin Luther University Halle-Wittenberg, 06118, Halle (Saale), Germany.
Ole PlessFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research Screening Port, 22525, Hamburg, Germany.
Dan RujescuDepartment of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, 1090, Austria.
Matthias JungInstitute for Physiological Chemistry (IPC), Medical Faculty of the Martin Luther University Halle-Wittenberg, 06114, Halle (Saale), Germany. matthias.jung@uk-halle.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the progression of late-onset Alzheimer disease (LOAD), there is a dysregulation and then a breakdown of the blood-brain barrier (BBB). An important pathological feature in the brains of patients is the accumulation of amyloid beta (Aβ) peptides. Their aggregation leads to the formation of particularly harmful Aβ oligomers (Aβ-O). Unfortunately, our understanding of changes in the blood-brain barrier, particularly with regard to the effects of Aβ-O, is still very limited.

methodsThis study investigated a LOAD-specific and induced pluripotent stem cell (hiPSC)-based in vitro model of the BBB for disease mechanisms and validated the findings in two independent laboratories. This study also investigated Aβ transport across the BBB. Furthermore, obtained in vitro findings were confirmed in the cerebrospinal fluid proteome of a LOAD patient cohort.

resultsControl and LOAD hiPSCs exhibited comparable efficiency in forming brain capillary endothelial-like cells (BCECs). Although transendothelial electrical resistance (TEER) assessments indicated no significant differences in barrier tightness between LOAD and control BCECs, high-throughput multiplex qPCR analysis revealed subtle alterations in barrier integrity. This included changes in various barrier markers, such as mucins (MUC1, MUC20), aquaporins (AQP5, AQP10), junctional transcripts (CLDNs, TJP1, OCLN), and receptors (LRP1, INSR, LSR), which were confirmed in LOAD patients. High-content imaging and flow cytometry indicated reduced cadherin 5 (CDH5) levels in LOAD BCECs. Importantly, the results also highlighted a difference in the transport of Aβ-O across the BBB.

conclusionThis model demonstrates a LOAD-relevant phenotype with decreased Aβ transport and alterations in key transcripts and could thus serve for future translational studies to rescue pathogenic phenotypes.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBlood-Brain BarrierBrainEndothelial CellsBiological TransportCells, CulturedHumansInduced Pluripotent Stem CellsAmyloid beta-PeptidesAmyloid betaApolipoprotein EBlood-brain barrierBrain capillary endothelial-like cellsHuman induced pluripotent stem cellsLate-onset Alzheimer disease

Identifiers

PMID41566484
PMCPMC12829042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.